Congrats to alumni MUVON Therapeutics AG on these milestones in the New Year 🎉 Deana Mohr-Haralampieva Steve Kappenthuler 👏 MUVON Therapeutics develops a novel therapy platform for the regeneration of skeletal muscle tissue based on autologous cells. Their initial area of focus is the treatment of stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life. More info here: https://lnkd.in/eg7JGcKX EPFL Innovation Park Groupe Mutuel #femtech #tech4eva #teamwork #startup #womenshealth #incontinence
MUVON Therapeutics AG announced the interim readout of its ongoing phase 2 clinical study ‘SUISSE MPC2’ and is delighted that the international Data Safety Monitoring Board recommended study continuation, putting the company on track for the release of the final data from the completed phase 2 study in Q3 2025. Deana Mohr-Haralampieva and Steve Kappenthuler are also attending the 43rd annual J.P. Morgan Healthcare conference - #JPM2025 - and are looking forward to discussing the future development plans with interested investor audiences and partners as the company is expecting to meet its capitalization objectives in Q1 of this year. 👉 Read the press release: https://lnkd.in/dQeqdDsF #regaincontrol #Urogynecology #wysszurichproject #wysszurich #celltherapy #regenerativemedicine #WomensHealth #HealthcareInnovation #TissueEngineering #PatientCare #ScientificExcellence